Kasvajatevastased ja immunomoduleerivate ainete ostmine

Kuressaare Hospital Foundation is buying a daratumumab-based cancer/immunomodulatory drug, so only suppliers that can (1) confirm full compliance with the tender terms, (2) submit the completed “HD Annex I Drug Description” form, and (3) price the product in the exact Excel cost sheet, should bid—conditional or non-conforming offers are rejected.

This is a 100% price-only (mandatory) procurement by Kuressaare Haigla for a 2-year supply of daratumumab-based cancer/immunomodulatory drugs, so any supplier that can deliver the exact active ingredient at the lowest tax-excluded unit price in EUR should bid.

Kuressaare Hospital is running an open, single-drug procurement (CPV 33600000-6) solely for daratumumab-containing cancer/immunomodulatory medicines—bidders must simply register their company details and confirm no exclusion grounds in the ESPD, making this a straightforward, low-barrier tender for any authorised daratumumab supplier.

Kuressaare Hospital is tendering a 2-year, non-binding supply of the mandatory monoclonal-antibody cancer drug Daratumumab 1800 mg/15 ml injection (72 vials) and will award solely on the lowest unit price ex-VAT, so only pharmaceutical wholesalers holding the exact product and able to quote the cheapest via-level price should bid.

Kuressaare Hospital seeks a 24-month supply of daratumumab-containing cancer/immunomodulatory drugs, delivered within 3 working days of monthly orders, with bidders required to prove clear title, provide quality certificates and accept that the stated maximum price can only fall—mandatory compliance with all delivery, documentation and liability terms in the draft contract.

Kuressaare Hospital wants to buy a single daratumumab-based cancer drug for ~2 years; bidders must hold a valid Estonian wholesale licence (mandatory) and the product must have a current marketing authorisation listed in Estonia’s drug register (mandatory).